Source: Eur Respir Rev, 28 (153) 190022; 10.1183/16000617.0022-2019
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Bridget F. Collins, Ganesh Raghu. Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis. Eur Respir Rev, 28 (153) 190022; 10.1183/16000617.0022-2019

Member's Comments

No comment yet.

Related content which might interest you: Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Antifibrotic treatment in progressive non-IPF fibrotic interstitial lung diseases Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019 Aquoaporin-1 expression in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Antifibrotic choice in idiopathic pulmonary fibrosis Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF) Year: 2018 Current and future therapeutic approaches in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: 693-703 Year: 2005 Beyond idiopathic pulmonary fibrosis: the world of progressive-fibrosing interstitial lung disease Source: Eur Respir Rev, 27 (150) 180110; 10.1183/16000617.0110-2018 Year: 2018 Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia Source: International Congress 2015 – Treatment of IPF Year: 2015 Genomic comparison of fibrotic rheumatoid arthritis-associated ILD and idiopathic pulmonary fibrosis Source: International Congress 2015 – Connective tissue disorders Year: 2015 Significance of histopathologic features suggesting connective tissue disease in idiopathic pulmonary fibrosis Source: International Congress 2015 – Connective tissue disorders Year: 2015 Negative outcome of prednisone in possible idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF clinical Year: 2016 Fibulin-1 is a novel biomarker of disease severity in pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Pirfenidone in idiopathic pulmonary fibrosis Source: Eur Respir J 2010; 36: 695-696 Year: 2010 Pirfenidone in idiopathic pulmonary fibrosis Source: Eur Respir J 2010; 35: 821-829 Year: 2010 17(R)-resolvinD1 improves MMP-9/TIMP-1 imbalance leading to amelioration of pulmonary fibrosis in mice Source: International Congress 2016 – ILD pathogenesis Year: 2016 Non-pulmonary comorbidities in idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Role of midkine in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Pulmonary hypertension in interstitial lung disease Source: Eur Respir J 2008; 31: 1357-1367 Year: 2008